SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors weigh an upcoming earnings report against the backdrop of potential U.S. cannabis rescheduling and regulatory shifts. The community remains deeply divided, with some betting on a turnaround fueled by medical growth and policy changes, while others express frustration over leadership, dilution, and long-term performance.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently experiencing significant market volatility driven by a disappointing first-quarter delivery report that missed analyst expectations, fueling intense community debate regarding the company's core automotive demand versus its long-term AI and robotics narrative. While some investors view the stock's weakness as a prime opportunity to buy the dip, others are aggressively betting against the position, citing concerns over declining sales, global competition, and the potential distraction of the anticipated SpaceX IPO.

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

Kelly Services is trending due to significant insider and institutional accumulation coupled with an exceptionally low float, fueling community speculation about a potential short squeeze. Investors are closely monitoring upcoming earnings and company conference calls as potential catalysts to ignite further momentum.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is experiencing significant volatility and elevated trading volume as investors aggressively speculate on potential buyout scenarios and M&A activity following unconfirmed media reports. The community is actively debating the company's valuation as a standalone rare-disease franchise versus its appeal as an acquisition target, with many traders closely watching abnormal after-hours trading patterns for signals of a catalyst.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space is currently trending as investors speculate on potential contract opportunities and the sector-wide tailwinds expected from an anticipated SpaceX IPO. While retail sentiment remains highly divided between bullish expectations for a short squeeze on the company's small float and bearish skepticism regarding the firm's lack of revenue and recent leadership turnover.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is experiencing heightened volatility as investors weigh aggressive geopolitical escalations in the Middle East and spiking oil prices against persistent market resilience. The community is actively debating whether current price action is a government-led stabilization effort, a classic bull trap, or a sign that the market is beginning to price in further macro instability.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following a positive trial update for its prostate cancer candidate, rinzimetostat, combined with a $125 million private placement financing. While some investors are expressing disappointment over the dose optimization results, the community is heavily debating the stock's future potential, with many pointing to its clean safety profile, strong cash position, and heavy institutional backing as signs of a potential long-term recovery.

Vine Hill Capital Investment Corp. is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on May 24, 2024 and is headquartered in Fort Lauderdale, FL.

CoinShares Plc.

CoinShares is capturing attention following its Nasdaq listing, with the community analyzing the firm's valuation gap compared to U.S. competitors and debating the impact of post-SPAC volatility. Investors are currently weighing the company's profitability and dividend potential against broader crypto market sentiment and geopolitical pressures affecting the sector.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing intense market activity as it joins the S&P 500 index, triggering mandatory buying from index funds and ETFs alongside continued speculative interest linked to AI infrastructure investments. The community is sharply divided, with bulls pointing to the company's critical role in the photonics supply chain and recent hyperscaler backing, while bears argue the valuation has reached unsustainable levels and is primed for a significant correction.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently under intense community scrutiny following a major exploit on the Drift Protocol, fueling debates about network security and institutional trust. While some investors are accumulating on dips based on developer momentum, others are concerned about market volatility and the long-term impact of regulatory pressures on the broader ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Solara Active Pharma Sciences Mangalore facility successfully completes USFDA inspection

Chennai: Solara Active Pharma Sciences Limited, an Active Pharmaceutical Ingredient provider, has announced … , and MFDS, Korea. Solara Active Pharma Sciences Ltd is a global …

Solara Active Pharma shares have rallied 25% in the last one month. According to Vijay Kumar Gupta, a SEBI-registered analyst, the stock is now consolidating near a critical resistance zone after a decisive breakout.&nbsp;Its momentum looks healthy, supported by solid volumes and improving fundamentals, he added.&nbsp;On the technical charts, it is trading above Ichimoku cloud with a bullish bias. The price action is hovering in the Fair Value Gap zone, yet to clear its upper resistance.&nbsp;Gupta also noted that its Commodity Channel Index (CCI) stands near 98, indicating moderate bullish momentum without overextension.&nbsp;&nbsp;TTM Squeeze (a technical indicator that identifies periods of low volatility) shows fading histogram bars, indicating that the stock may experience a possible pause before a fresh move. Additionally, the volume consolidation suggests healthy digestion of gains.<stembedurl>https://stocktwits.com/VijayGuptaAdvisory/message/621871688</stembedurl>Fundamentally, Solara is one of India’s leading API manufacturers, focusing on chronic therapy segments like pain management and inflammation.&nbsp;Recent performance has been boosted by operational turnaround and restructuring efforts following its merger phase. It reported a 15% revenue growth in the March quarter, which also saw its profits tripling to ₹41 crore. Gross margins have expanded significantly due to better product mix. Going ahead, its debt reduction and working capital efficiency remain key positives.&nbsp;Gupta also noted that the management commentary hinted at stronger export orders and improved utilization in FY26.&nbsp;What’s Driving The Sentiment?According to Gupta, investor interest is returning in niche pharma plays, driven by financial deleveraging and margin expansion. Additionally, the global focus on API de-risking by clients is benefiting Indian manufacturers.&nbsp;However, data on Stocktwits shows that retail sentiment has been ‘bearish’ on this counter for a few weeks.&nbsp;<figure class="image"><img style="aspect-ratio:808/111;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_23_111838_png_d20ae7d100.webp" alt="Screenshot 2025-07-23 111838.png" width="808" height="111"><figcaption>Solara sentiment and message volume on July 23 as of 11:20 am IST. | source: Stocktwits</figcaption></figure>Solara shares have declined 4% year-to-date (YTD).For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies. (Photo by Artur Widak/NurPhoto via Getty Images)

Solara Stock In Pause Mode Before Next Move? SEBI RA Vijay Gupta Sees Healthy Setup

 Solara Pharma has gained 25% in a month and is now consolidating near a key resistance zone.

Equity

 Solara Pharma has gained 25% in a month and is now consolidating near a key resistance zone.



Stock Market Today: Power Grid, Tata Motors, Zomato Among Top Losers

Over 3,300 stocks saw declines, wiping market capitalization down to 411.3 trillion The Indian stock market experienced a steep decline on January 27, 2025, with major indices and broader markets showing substantial losses. The downturn was marked by widespread selling across large-cap, mid-cap, and small-cap stocks, reflecting heightened investor anxiety. Major Indices Suffer Significant Losses The BSE Sensex plunged 842.5 points in intraday trade, touching a low of 75,348. The Nifty50 on the National Stock Exchange also witnessed a sharp decline, falling 265.4 points to hit a low of 22,826.8. These declines highlight the intense selling pressure across the Indian equity market, as investors reacted to both domestic and global uncertainties. Large-Cap Stocks Under Pressure Large-cap stocks bore the brunt of the sell-off, with heavyweights like Power Grid, Tata Motors, Zomato , IndusInd Bank, HCL Tech, Tech Mahindra, TCS, Bharti Airtel, Infosys, Reliance Industries, L&T, Bajaj Finance, Bajaj Finserv, and HDFC Bank losing between 1% and 3.6%.

Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. Its products include Albendazole, aprepitant, artesunate, brivaracetam, bumetanide, buspiron, cetirizine dihydrochloride, chlorpromazine, cinacalcet hydrochloride, citicoline sodium, colchicine, colesevelam, colestipol, cycloserine, dipyridamole, disulfiram, dolutegravir, edaravone, efinaconazole, ethacrynic acid, etomidate, felbamate, flecainide acetate, flucytosine, gabapentin, hydralazine, ibuprofen, imiquimod, indapamide, lanthanum carbonate octahydrate,levetiracetam, lurasidone, mebendazole, mefenamic acid, mesalamine, mesna, methohexital, methoxsalen, mirabegron, mycophenolate mofetil, naproxen base, nizatidine, obeticholic acid, alanzapine, patiromer sorbitex calcium, pentoxifyline, pitavastatin calcium, posaconazole, praziquantel, ranitidine, rebamipide, rifaximin, rotigotine, safinamide, sapropterin, sevelamer carbonate, succinylcholine, sucroferric oxyhydroxide, sugammadex, tioconazole, tranexamic acid and zileuton. The company was founded on February 23, 2017 and is headquartered in Chennai, India.

Current Price	474.80
Prev Close	460.50
Open	442.00
Dividend Yield	0.00%
50-Day Moving Average	476.43
Beta	0.12
Avg. Volume	94,129.84
PE Ratio	-111.93

52-Week High	734.40
52-Week Low	422.00
Market Capitalization	22.18B
EPS (Annual)	0.1353
Price to Book	1.69
Revenue Per Employee	4.34M

SOLARA.NSE
Solara Active Pharma Sciences Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest SOLARA.NSE News

SOLARA.NSESolara Active Pharma Sciences Ltd.